Nature Bioentrepreneur | Trade Secrets

How VCs build companies today

We published in the December issue of Nature Biotechnology a news analysis detailing some of the funding models being used by today’s life science investors. Some are looking to expand syndicates, ensuring that funding is there for follow-on rounds. One is sometimes providing huge A rounds by itself. And though many favor an “asset-based” approach, the R&D platform engine is not as dead as might be thought. 

BACK TO ARTICLE

Tell a Friend

Please ensure that your friend is content to receive an email from us with a link to the article. Select the following link to view our Privacy Policy.

BACK TO ARTICLE